ArticlePloS one2006
Mapping the antigenicity of the parasites in Leishmania donovani infection by proteome serology.
Article in PloS one, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 59 citations in OpenAlex.
- Immunoproteomics and phage display in the context of leishmaniasis complexity.Frontiers in immunology · 2023Review
- An immunoproteomic approach to identifying immunoreactive proteins inPathogens and global health · 2019Article
- Proteomic Analysis Reveals a Predominant NFE2L2 (NRF2) Signature in Canonical Pathway and Upstream Regulator Analysis ofFrontiers in immunology · 2019Article
- Impact of Leishmania donovani infection on the HLA I self peptide repertoire of human macrophages.PloS one · 2018Article
- Identification of Leishmania donovani antigen in circulating immune complexes of visceral leishmaniasis subjects for diagnosis.PloS one · 2017Article
- Article
- Ability of immunodiagnostic tests to differentiate between dogs naturally infected with Leishmania infantum and Leishmune(®)-vaccinated dogs.Veterinary research communications · 2015Article
- Proteome profiling of human cutaneous leishmaniasis lesion.The Journal of investigative dermatology · 2015Article
- An Optimized Fluorescence-Based Bidimensional Immunoproteomic Approach for Accurate Screening of Autoantibodies.PloS one · 2015Article
- Article
- Biomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis - discovery and implications.Frontiers in immunology · 2014Review
- rKLO8, a novel Leishmania donovani - derived recombinant immunodominant protein for sensitive detection of visceral leishmaniasis in Sudan.PLoS neglected tropical diseases · 2013Article
- Immunodominant antigens of Leishmania chagasi associated with protection against human visceral leishmaniasis.PLoS neglected tropical diseases · 2012Article
- Improved canine and human visceral leishmaniasis immunodiagnosis using combinations of synthetic peptides in enzyme-linked immunosorbent assay.PLoS neglected tropical diseases · 2012Article
- Vaccine Development Against Leishmania donovani.Frontiers in immunology · 2012Article
- Single dose novel Salmonella vaccine enhances resistance against visceralizing L. major and L. donovani infection in susceptible BALB/c mice.PLoS neglected tropical diseases · 2011Article
- Two-dimensional difference gel electrophoresis (DIGE) analysis of sera from visceral leishmaniasis patients.Clinical proteomics · 2011Article
- A search for Trypanosoma brucei rhodesiense diagnostic antigens by proteomic screening and targeted cloning.PloS one · 2010Article
- The Leishmania infantum PUF proteins are targets of the humoral response during visceral leishmaniasis.BMC research notes · 2010Article
- Proteome-based analysis of serologically defined tumor-associated antigens in cutaneous lymphoma.PloS one · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeishmaniasis defines a cluster of protozoal diseases with diverse clinical manifestations. The visceral form caused by Leishmania donovani is the most severe. So far, no vaccines exist for visceral leishmaniasis despite indications of naturally developing immunity, and sensitive immunodiagnostics are still at early stages of development. METHODOLOGY/PRINCIPLE
findingsEstablishing a proteome-serological methodology, we mapped the antigenicity of the parasites and the specificities of the immune responses in human leishmaniasis. Using 2-dimensional Western blot analyses with sera and parasites isolated from patients in India, we detected immune responses with widely divergent specificities for up to 330 different leishmanial antigens. 68 antigens were assigned to proteins in silver- and fluorochrome-stained gels. The antigenicity of these proteins did not correlate with the expression levels of the proteins. Although some antigens are shared among different parasite isolates, there are extensive differences and no immunodominant antigens, but indications of antigenic drift in the parasites. Six antigens were identified by mass spectrometry. CONCLUSIONS/SIGNIFICANCE: Proteomics-based dissection of the serospecificities of leishmaniasis patients provides a comprehensive inventory of the complexity and interindividual heterogeneity of the host-responses to and variations in the antigenicity of the Leishmania parasites. This information can be instrumental in the development of vaccines and new immune monitoring and diagnostic devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.